Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Revenue (2016 - 2025)

Adma Biologics' Revenue history spans 14 years, with the latest figure at $139.2 million for Q4 2025.

  • For Q4 2025, Revenue rose 18.39% year-over-year to $139.2 million; the TTM value through Dec 2025 reached $510.2 million, up 19.63%, while the annual FY2025 figure was $510.2 million, 19.63% up from the prior year.
  • Revenue reached $139.2 million in Q4 2025 per ADMA's latest filing, up from $134.2 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $139.2 million in Q4 2025 to a low of $16.0 million in Q1 2021.
  • Average Revenue over 5 years is $77.1 million, with a median of $74.5 million recorded in 2022.
  • Peak YoY movement for Revenue: soared 320.63% in 2022, then fell 19.84% in 2023.
  • A 5-year view of Revenue shows it stood at $55.0 million in 2021, then dropped by 9.12% to $50.0 million in 2022, then skyrocketed by 47.86% to $73.9 million in 2023, then surged by 59.06% to $117.5 million in 2024, then grew by 18.39% to $139.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Revenue are $139.2 million (Q4 2025), $134.2 million (Q3 2025), and $122.0 million (Q2 2025).